# Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)

> **NCT00328653** · PHASE2,PHASE3 · COMPLETED · sponsor: **Santen SAS** · enrollment: 118 (actual)

## Conditions studied

- Conjunctivitis, Vernal

## Interventions

- **DRUG:** Cyclosporine NOVA22007 0.05%
- **DRUG:** Cyclosporine NOVA22007 0.1%
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT00328653
- **Lead sponsor:** Santen SAS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-02-22
- **Final completion:** —
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2021-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00328653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00328653, "Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00328653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*